Brain Metastases in Oncogene-Addicted Non-Small Cell Lung Cancer Patients: Incidence and Treatment

Jordi Remón(Vall d'Hebron Hospital Universitari), Benjamin Besse(Institut Gustave Roussy)

Frontiers in Oncology

April 11, 2018

10.3389/fonc.2018.00088

Cited by 77

Related Papers

Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer

|New England Journal of Medicine|2013|3.4k

Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation

|New England Journal of Medicine|2021|1.8k

Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer

|New England Journal of Medicine|2020|835

Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial

|The Lancet Oncology|2022|738

Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer

|Nature Medicine|2022|637